Hand-foot syndrome and sorafenib: Views from pharmacologist, dermatologist and medical oncologist;Sorafénib et syndrome main-pied: Points de vue du pharmacologue, du dermatologue et de l'oncologue médical

Bulletin du Cancer

Volumn 96, Issue 2, 2009, Pages 191-197

  Milano, G ^a   Mortier, L ^b   Digue, L ^c   Desmedt, E ^b   Ravaud, A ^c  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Cancer; Hand and foot dysesthesia; Hyperkeratosis; RAF; Sorafenib

Indexed keywords

CAPECITABINE; CELECOXIB; CORTICOSTEROID; CYTARABINE; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; NAVELBINE; RAF PROTEIN; SORAFENIB; SUNITINIB;

AREA UNDER THE CURVE; BIOTRANSFORMATION; CANCER CHEMOTHERAPY; CLINICAL FEATURE; DYSESTHESIA; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; PAIN; PHYSICIAN; PRIMARY PREVENTION; REVIEW; SKIN TOXICITY; SKIN ULCER;

BENZENESULFONATES; DERMATOLOGY; DRUG ERUPTIONS; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MEDICAL ONCOLOGY; PHARMACY; PROTEIN KINASE INHIBITORS; PYRIDINES; SKIN; SYNDROME;

EID: 66349104827     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0814     Document Type: Review

References (17)

1. Schlessinger J. Cell signaling by receptor tyrosines-kinases. Cell 2000 ; 103 : 211-225
2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear: cell renal cell carcinoma. N Engl J Med 2007 ; 356 : 125-134 (Pubitemid 46089673)
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 ; 359 : 378-390
4. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. Role of RAF in vascular protection from distinct apoptotic stimuli. Science 2003 ; 301 : 94-96 (Pubitemid 36801568)
5. Dajee M, Tarutani M, Deng H, Cai T, Khavari PA. Epidermal RAS blockade demonstrates spatially localized RAS promotion of proliferation and inhibition of differentiation. Oncogene 2002 ; 21 : 1527-1538 (Pubitemid 34226140)
6. Tarutani M, Cai T, Dajee M, Khavari PA. Inducible activation of RAS and RAF in adult epidermis. Cancer Res 2003 ; 63 : 319-323 (Pubitemid 36152487)
7. Scholl FA, Dumesic PA, Barragan DI, Harada K, Bissonauth V, Charron J, et al. Mek1/2 MAPK kinases are essential for mammalian development, homeostasis, and RAF-induced hyperplasia. Dev Cell 2007 ; 12 : 615-629 (Pubitemid 46523646)
8. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007 ; 12 : 426-437 (Pubitemid 46698720)
9. Houk BE, Bello CL, Michaelson MD, Bukowski RM, Redman BG, Hudes GR, et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKDP) approach. Proc Am Soc Clin Oncol 2007 ; 241s : Abst. 5027.
10. Milano G, Etienne-Grimaldi MC, Mari M, Lasalle S, Formento JL, Francoual M, et al. Candidate mechanism for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008 ; 66 : 88-95.
11. Dajee M, Tarutani M, Deng H, Cai T, Khavari PA. Epidermal RAS blockade demonstrates spatially localized RAS promotion of proliferation and inhibition of differentiation. Oncogene 2002 ; 21 : 1527-1538 (Pubitemid 34226140)
12. Tarutani M, Cai T, Dajee M, Khavari PA. Inducible activation of RAS and RAF in adult epidermis. Cancer Res 2003 ; 63 : 319-323 (Pubitemid 36152487)
13. Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974 ; 148 : 90-92
14. Janusch M, Fischer M, Marsch W, Holzhausen HJ, Kegel T, Helmbold P. The hand-foot syndrome: a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006 ; 16 : 494-499 (Pubitemid 44861822)
15. Vukelja SJ, Lombardo FA, James WD, Weiss RB. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989 ; 111 : 688-689
16. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology 2002 ; 12 : 31-37
17. Billemont B, Méric JB, Issedine H, Taillade L, Sultan-Amar V, Rixe O. Angiogenesis and renal cell carcinoma. Bull Cancer 2007 ; 94 : S232-40.